The Psychotomimetic Effects of Intravenous Delta-9-Tetrahydrocannabinol in Healthy Individuals: Implications for Psychosis

  title={The Psychotomimetic Effects of Intravenous Delta-9-Tetrahydrocannabinol in Healthy Individuals: Implications for Psychosis},
  author={D. D’Souza and Edward Perry and Lisa Macdougall and Yola Ammerman and T. Cooper and Y. Wu and G. Braley and R. Gueorguieva and J. Krystal},
  • D. D’Souza, Edward Perry, +6 authors J. Krystal
  • Published 2004
  • Psychology, Medicine
  • Neuropsychopharmacology
  • Recent advances in the understanding of brain cannabinoid receptor function have renewed interest in the association between cannabinoid compounds and psychosis. In a 3-day, double-blind, randomized, and counterbalanced study, the behavioral, cognitive, and endocrine effects of 0, 2.5, and 5 mg intravenous delta-9-tetrahydrocannabinol (Δ-9-THC) were characterized in 22 healthy individuals, who had been exposed to cannabis but had never been diagnosed with a cannabis abuse disorder. Prospective… CONTINUE READING
    782 Citations
    Blunted Psychotomimetic and Amnestic Effects of Δ-9-Tetrahydrocannabinol in Frequent Users of Cannabis
    • 208
    • PDF
    The acute effects of synthetic intravenous Delta9-tetrahydrocannabinol on psychosis, mood and cognitive functioning.
    • 242
    • Highly Influenced
    Descriptive Psychopathology of the Acute Effects of Intravenous Delta-9-Tetrahydrocannabinol Administration in Humans
    • 5
    • Highly Influenced
    • PDF
    Does olanzapine inhibit the psychomimetic effects of Δ9-tetrahydrocannabinol?
    • 34
    Delta-9-tetrahydrocannabinol increases striatal glutamate levels in healthy individuals: implications for psychosis
    • 25
    • PDF


    Cognitive and subjective dose-response effects of acute oral Δ9-tetrahydrocannabinol (THC) in infrequent cannabis users
    • 293
    • Highly Influential
    Chronic (-)-delta9-tetrahydrocannabinol treatment induces sensitization to the psychomotor effects of amphetamine in rats.
    • 147
    Endocannabinoids in cognition and dependence.
    • 128
    Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
    • 2,842
    Cannabinoid/anandamide system and schizophrenia: is there evidence for association?
    • 46
    The psychoactive ingredient of marijuana induces behavioural sensitization
    • 38
    Comparative Effects of Alcohol and Marijuana on Mood, Memory, and Performance
    • 187
    Increase in meso-prefrontal dopaminergic activity after stimulation of CB1 receptors by cannabinoids.
    • 45